Blood Transfusion Diagnostics Market to Reach US$ 7.7 Billion by 2034, Driven by Rising Blood Disorders and Advances in Screening Technologies | Latest Report TMR

The global blood transfusion diagnostics market was valued at US$ 4.6 Billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2034, reaching more than US$ 7.7 Billion by the end of 2034. Market growth is driven by the rising global prevalence of blood disorders, increasing number of surgeries and road accidents, and the rapid expansion of the geriatric population worldwide.

Access key findings and insights from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85892

Market Overview

Blood transfusion diagnostics comprise a range of immunohematology tests that are essential prior to transfusion of whole blood or blood components such as red blood cells, plasma, and platelets. These diagnostics ensure donor-recipient compatibility and screen blood for transfusion-transmissible infections, thereby playing a critical role in patient safety.

The market includes two primary product categories: analytical instruments that allow continuous loading and unloading of samples with automated result recording, and kits and reagents, which are consumable components required repeatedly for conducting diagnostic tests. Pre-transfusion testing typically includes ABO blood typing, Rh typing, extended phenotyping, red blood cell antibody screening, and serological and molecular disease screening.

With manufacturers continuously innovating to enhance test accuracy, speed, and workflow efficiency, high-throughput automated instruments are increasingly being adopted across blood banks and transfusion centers. Given the critical importance of ensuring safe transfusion blood, the blood transfusion diagnostics market is expected to witness sustained growth over the forecast period.

Key Market Growth Drivers

Rise in Prevalence of Blood Disorders

The increasing incidence of blood-related disorders is a major factor fueling growth of the blood transfusion diagnostics market. Conditions such as leukemia, thalassemia, sickle cell anemia, and hemophilia often require frequent blood transfusions, thereby increasing the need for accurate and reliable transfusion diagnostics.

According to the Leukemia and Lymphoma Society, an estimated 59,610 new leukemia cases were diagnosed in the U.S. in 2023, with approximately 23,710 deaths attributed to the disease. Furthermore, the World Health Organization estimates that around 5% of the global population are carriers of genes responsible for hemoglobin disorders, with over 300,000 infants born annually with severe hemoglobin conditions. These statistics highlight the critical need for safe, well-screened transfusion blood.

Emergence of Innovative Technologies for Improving Blood Donation and Storage

Technological innovation is reshaping the blood transfusion diagnostics landscape. Automated donor management systems have streamlined workflows, reduced errors, and enhanced operational efficiency across blood banks and transfusion centers.

Advanced software platforms and mobile applications have improved donor recruitment and engagement by enabling appointment scheduling, reminders, and post-donation care communication. Cloud-based systems have further enhanced data security, traceability, and accessibility of donor information, ensuring better tracking from donor to recipient. These advancements are creating new growth opportunities within the blood transfusion diagnostics market.

Explore our report to uncover in-depth insights - https://www.transparencymarketresearch.com/blood-transfusion-diagnostics-market.html

Market Segmentation

• Product Type

o Instruments
Blood Grouping Instruments
Others

o Kits and Reagents
Blood Grouping Kits and Reagents
Others

• Application

o Blood Grouping
ABO Blood Grouping
Rh Blood Grouping
Red Blood Cell Antibody Screening
Extended Phenotyping
Cross Matching Tests

o Disease Screening
Molecular Disease Screening
Serological Disease Screening

• End-user

o Blood Banks
o Blood Donation/Transfusion Centers
o Others

Regional Outlook

North America - Leading Region
North America held a dominant share of the blood transfusion diagnostics market in 2023, supported by advanced healthcare infrastructure, higher awareness regarding blood safety, and increased healthcare spending. The region continues to witness strong adoption of innovative diagnostic solutions.

In the United States, companies are actively launching new technologies to strengthen their market positions. For instance, in March 2024, Roche received U.S. FDA approval for its cobas Malaria test for use on the cobas 6800/8800 Systems, aimed at reducing the risk of malarial infection from transfused blood products.

Europe
In Europe, rising prevalence of sickle cell anemia due to global population movement is increasing demand for safe transfusion blood. Although classified as a rare disease in the European Union, the growing patient population has prompted regulatory bodies and manufacturers to enhance blood availability and screening practices, supporting regional market growth.

Asia Pacific
Asia Pacific is expected to witness the fastest growth rate during the forecast period. The region is experiencing a rapid increase in its geriatric population and a growing prevalence of blood-related disorders in countries such as Japan, India, and China. Market expansion is further supported by increasing device approvals, rising adoption of automated diagnostic instruments, and the entry of multinational companies.

Analysis of Key Players

• Grifols, S.A.
• F. Hoffmann-La Roche Ltd.
• Abbott
• Bio-Rad Laboratories, Inc.
• Werfen, S.A.
• QuidelOrtho Corporation
• AliveDx Holdings Finance Company Ltd
• BAG Diagnostics GmbH
• Diasorin S.p.A.
• Prestige Diagnostics U.K. Ltd.
• Atlas Medical GmbH
• Lorne Laboratories Limited

These companies focus on product innovation, regulatory compliance, strategic collaborations, and geographic expansion to strengthen their market positions. Each player is profiled in the market research report based on company overview, financial performance, business strategies, product portfolio, and recent developments.

Key Developments

• April 2024: Grifols received CE mark approval for its new Procleix ArboPlex Assay, an automated nucleic acid test for detecting chikungunya, dengue, West Nile, and Zika viruses in blood donors.

• November 2023: AliveDx announced that its manufacturing facilities in Switzerland and the UK received IVDR certification (EN ISO 13485:2016), enabling continued operations within the European Union.

• June 2023: Werfen expanded its collaboration with Seegene Inc. for co-development of syndromic qPCR assays tailored to Spanish and Portuguese healthcare systems.

Why Buy This Report?

• Obtain comprehensive market size, trend, and forecast analysis through 2034
• Identify key growth drivers, challenges, and emerging opportunities
• Understand competitive dynamics and key player strategies
• Gain region-wise and segment-wise market insights
• Support informed business, investment, and expansion decisions

Buy this Premium Research Report for exclusive, in-depth insights - https://www.transparencymarketresearch.com/checkout.php?rep_id=85892

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com

This release was published on openPR.